Mitral Valve (Repair & Replacement)JACCFriday, August 28, 2026

Sex-Based Differences in Outcomes After Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation.

1 min read·By E. Nolan Beckett, MD·Source: JACC. Advances

Key Numbers

40.6%

81% vs 65

47% vs 37

22% vs 17

From The Valve Wire

In a single-center M-TEER cohort of 293 patients (40.6% women) followed from 2014 to 2025, sex did not predict 6-month all-cause mortality (22% men vs 17% women, adjusted OR 0.93, P = 0.83) or heart failure rehospitalization (10% vs 13%, adjusted OR 1.15, P = 0.73).

Women presented older, with worse baseline 6-minute walk distance and a lower proportion of functional MR, but achieved comparable functional improvement at 6 months.

This is observational data from a single German center over a decade during which device iterations, patient selection, and operator experience all evolved — confounders no adjustment fully controls.

The sample is modest for a mortality endpoint, and 6 months is short: sex-based divergence in M-TEER outcomes, if it exists, may emerge later, as COAPT's longer follow-up suggested for the overall population.

Source Abstract

BACKGROUND: Whether differences in outcomes exist between men and women after transcatheter edge-to-edge repair is currently unknown. OBJECTIVES: This study investigated sex-based differences in outcomes after mitral transcatheter edge-to-edge repair (M-TEER) for severe mitral regurgitation (MR). METHODS: Patients undergoing M-TEER were included from May 2014 to October 2025. The prognostic impact of sex was investigated with regard to the primary endpoint all-cause mortality at 6 months. The secondary endpoints comprised the reduction of MR, rehospitalization for heart failure (HF) and functional capacity as assessed by the 6-minute walk test. RESULTS: Of the 293 patients enrolled in the study, 119 (40.6%) were women. Compared with men, women had a similar severity of MR independent of its etiology. The prevalence of coronary artery disease (81% vs 65%; P = 0.002), and the proportion of functional MR (47% vs 37%) were higher in males. The risk of all-cause mortality at 6 months did not significantly differ in males and females (22% vs 17%; P = 0.301; adjusted OR = 0.929; 95% CI: 0.474-1.822; P = 0.830), paralleled by comparable rates of HF-related rehospitalization (10% vs 13%; P = 0.576; adjusted OR = 1.151; 95% CI: 0.520-2.548; P = 0.729). By contrast, women demonstrated a significantly lower functional capacity at baseline (P = 0.001). Interestingly, at 6 months mean improvement of functional capacity was similar between male and female patients (P = 0.778). CONCLUSIONS: Women undergoing M-TEER presented at a more advanced age and with higher symptom burden than men, potentially reflecting sex-specific clinical trajectories and differing MR etiologies. However, midterm outcomes, including all-cause mortality and HF rehospitalization, were comparable between sexes.

Authors: Sauter RJ, Schupp T, Sauter M, Sieburg T, Britsch S et al.

Read the Original

Full article at JACC. Advances

Open at JACC. Advances →

The Valve Wire summarizes; we link out to primary sources for verification.

More in Mitral Valve (Repair & Replacement)

Elsewhere in Today’s Issue

← Today’s digest Full digest for Friday, August 28, 2026 →